Tarsier Pharma News
13 articles
growth-positive
/PRNewswire/ -- Tarsier Pharma®, Ltd, a late-clinical stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the...
Tarsier Pharma Ltd, a late-clinical stage ophthalmic biopharmaceutical company, has appointed Ms. Ashley Kline as Chief Commercial Officer. With over 15 years of experience in biopharmaceuticals, particularly in ophthalmology, Kline will lead the commercial planning for Tarsiers pipeline, including its lead asset, TRS01. Her previous roles at Dompé Farmaceutici and other companies have equipped her with the expertise to bring novel therapies to market. Tarsier is focused on developing treatments for blinding ocular diseases, with TRS01 entering its second phase 3 trial. This appointment is seen as a pivotal step in Tarsiers growth, aiming to build commercial franchises in uveitis and other blinding conditions.
Management Changes
growth-positive
Tarsier Pharma announces development of TRS02, a potential immunomodulator, for the treatment of retinal diseases with sustained-release intravitreal formulation
Tarsier Pharma has announced the development of TRS02, a slow-release formulation of TRS for intravitreal injection, to treat retinal diseases. TRS is a breakthrough proprietary technology platform with an anti-inflammatory Mechanism-of-Action. TRS02 is intended to be injected into the back of the eye for the treatment of back-of-the-eye indications with underlying inflammatory pathology. The company has achieved significant pre-clinical milestones in TRS02 development, bringing it closer to IND submission. Tarsier Pharma is focused on developing technologies to treat ocular back and front of the eye blinding diseases.
Expand
growth-positive
How one female CEO overcame adversity to find a cure for Uveitis
Tarsier Pharma, a biotech company founded by Dr. Daphne Haim-Langford, is developing medical solutions for autoimmune and inflammatory eye diseases. The companys flagship product combats Uveitic glaucoma, a condition that can cause blindness and is currently in stage three of its clinical trials. Since its founding, Tarsier Pharma has raised $20 million from investors including Indian biopharmaceutical giants Sun Pharmaceutical Industries Ltd. and BioLite Life Sciences. The company plans to file its trial results to the FDA by 2023.
InvestmentExpand
growth-positive
Tarsier™ Pharma is launching a dedicated website about uveitic glaucoma
Tarsier Pharma has launched an education website about the disease uveitic glaucoma to increase awareness among the general public. Uveitic glaucoma is a severe and blinding disease that consists of non-infectious uveitis and glaucoma. The companys lead product candidate, TRS01, is a fast-acting immunomodulator for the treatment of non-infectious anterior uveitis in patients with uveitic glaucoma. Tarsier Pharma aims to develop optimal therapies for this patient population.
Customers
growth-positive
Israeli pharmaceutical executive wins 2021 EU Prize for Women Innovators
Dr. Daphne Haim-Langford, founder and CEO of Tarsier Pharma, won the 2021 EU Prize for Women Innovators. Tarsier Pharma, founded in 2016, develops treatments for autoimmune inflammatory ocular diseases. The prize comes with a €100,000 cash prize. Tarsier Pharma has received funding from the EUs Horizon Europe program. Earlier this year, Tarsier Pharma raised capital to perform a phase III clinical trial of one of its solutions, TRS, in the US and Europe.
Investment
growth-positive
Tarsier Pharma Raises Capital to Execute Phase-3 Clinical Trial
Tarsier Pharma has raised capital to execute a phase-3 clinical trial of its TRS01 program in the US and Europe. The company obtained all necessary regulatory approvals and plans to enroll the first patient in Q4 of 2021. Tarsiers TRS technology is a novel immunomodulator molecule that has shown significant improvement in signs and symptoms of uveitis. The CEO of Tarsier Pharma expressed excitement about bringing their lead product to market and progressing the development of pipeline projects for other blinding diseases.
Investment
growth-positive
Tarsier Pharma's Positive End-of-Phase 2 Meeting with the U.S. FDA Sets Stage for TRS01 Phase III Program in Uveitis BioSpace
Tarsier Pharma has successfully completed an End-of-Phase 2 meeting with the FDA for its TRS01 Phase 3 program in uveitis. The company received important feedback on its trial design and program, paving the way for a future NDA submission. TRS01 is a novel immunomodulator drug for treating Active Anterior Non-Infectious Uveitis. Tarsier Pharma plans to initiate the pivotal Phase 3 study in 2021. Positive results from the Phase 1/2 clinical trial of TRS01 showed significant improvement in signs and symptoms of Uveitis. Tarsier Pharma is focused on developing TRS, a breakthrough platform technology for the treatment of ocular diseases.
InvestmentExpand
growth-positive
Tarsius Pharma Achieves Positive Results in Proof of Concept Study for TRS01 Targeting Uveitis
Tarsius Pharma announced positive results from the GADOT 20/20 trial of its TRS01 drug for treating Active Anterior Non-Infectious Uveitis. The trial demonstrated significant improvement in critical measures such as ACC, pain reduction, and increased visual acuity. The high-dose usage of TRS01 was found to be superior to the low-dose in various measures. The results suggest progress towards the development of a novel class of ocular therapeutics. Tarsius Pharma is focused on developing TRS, a breakthrough platform technology for the treatment of blinding ocular diseases.
Customers
growth-positive
Tarsius Pharma Completes Patient Enrollment in Clinical Trial of TRS01 in Patients With Non-infectious Uveitis
Tarsius Pharma has announced the completion of patient enrollment in its Phase I/II trial of TRS01 for the treatment of ocular inflammation. The trial, called GADOT 20/20, aims to evaluate the safety and efficacy of TRS01 in patients with active anterior non-infectious uveitis. Despite the challenges posed by the COVID-19 pandemic, the company exceeded its enrollment target and enrolled 16 patients. Tarsius Pharma expects to announce topline results from the trial in the second half of 2020. The completion of enrollment marks an important milestone for the company and highlights the urgent need for better treatment options for patients with uveitis. Tarsius Pharma plans to commence the Phase III trial in early 2021. The companys investors include Sun Pharmaceuticals and BioLight Life Sciences Ltd.
Customers
growth-positive
Tarsius Pharma Announces Granting of Orphan Drug Designation for TRS by the European Medicines Agency
Tarsius Pharma has received orphan drug designation from the European Medicines Agency (EMA) for its TRS for the treatment of non-infectious uveitis. The EMA acknowledged the significant benefit of TRS for uveitis patients with glaucoma who are not eligible for corticosteroid treatment. This designation allows Tarsius Pharma to proceed to Phase I/II clinical trials. Ocular inflammatory diseases, including uveitis, impose a significant burden on society and can lead to vision loss and blindness. Tarsius Pharmas TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases. Tarsius Pharma was established in 2016 and has received funding from the European Unions Horizon 2020 program. The companys investors include Sun Pharmaceuticals, BioLight Life Sciences Ltd, private investors, and family offices.
Customers
growth-positive
Tarsius Pharma Announces FDA Acceptance of IND Application for TRS01
Tarsius Pharmas Investigational New Drug (IND) application for TRS01 has been accepted by the FDA. TRS01 is a breakthrough, bio-inspired platform technology for the treatment of blinding ocular diseases. The acceptance of the IND will allow Tarsius to initiate enrollment in its planned Phase I/II clinical trial of TRS01. The study aims to determine the safety profile, recommended dose, and potential effect of TRS01 in ocular inflammation. Tarsius Pharma is focused on developing innovative therapeutic solutions to prevent blindness and is backed by Sun Pharmaceuticals and other private investors. Ocular inflammatory diseases impose a significant burden on society, and the TRS Platform Technology has the potential to effectively treat a broad array of autoimmune and inflammatory ocular diseases.
Customers
growth-positive
Tarsius Pharma Receives 2.4 Million Euros EU Grant to Combat Blinding Diseases
Israel-based Tarsius Pharma Ltd. has been awarded a 2.4 million euros grant from Horizon 2020, the European Union’s research and innovation program. The funding will be used to start clinical development for Tarsius technology in the treatment of blindness-causing ocular diseases. Tarsius Pharma Ltd. develops treatments for autoimmune and inflammatory diseases that damage the eye. The company is based in Zikhron Yaakov, Israel. Horizon 2020 is carried out in Israel by the Israel Innovation Authority through the Israel-Europe Research and Development Directorate.
Investment
growth-positive
Sun Pharma to acquire 18.75% stake in Israel's Tarsius for $3m
Sun Pharmaceutical Industries is acquiring an 18.75% stake in Tarsius Pharma for a cash consideration of $3 million.
Acquisition
